Welcome to BioSeeker Group!

Immunomodulators

In this section you will find Therapeutics Line of Treatment Immunomodulators market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.

9 Item(s)

per page

Set Ascending Direction
  1. The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave

    $1,950.00
    Published by BioSeeker Group on Nov 22nd, 2005
    The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More

  2. Immunotherapy in Oncology: Gaining Momentum

    $2,950.00
    Published by BioSeeker Group on Aug 4th, 2006
    The immunotherapy field in cancer has never been more potent than it is right now, including block buster drugs like Avastin, Erbitux, and Rituxan. Antibodies are making the headlines but cancer vaccines are not far away. The recent approval of Gardasil, a cervical cancer vaccine, will certainly become a strong representative of its kind. Future challenges for the industry lie in discovering strong antigens, effective immunomodulators and developing suitable delivery technologies. Learn More

  3. Immunotherapy in Oncology Drug Pipeline Update

    $3,675.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 830 companies plus partners who are today developing 1578 cancer immunotherapy drugs in 4062 developmental projects in cancer across 535 different targets. In addition, there are 19 suspended drugs and another 624 drugs where development has been ceased. Learn More

  4. Cytokine Therapy in Oncology Drug Pipeline Update

    $1,495.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 80 companies plus partners who are today developing 99 cytokine drugs in 195 developmental projects in cancer across 20 different targets. In addition, there is 1 suspended drug and another 11 drugs where development has been ceased. Learn More

  5. Competitive Outlook on Non-Antibody Based Cancer Vaccines

    $1,950.00
    Published by BioSeeker Group on Aug 3rd, 2006
    Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More

  6. Cancer Vaccines Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 314 companies plus partners who are today developing 386 cancer vaccine drugs in 784 developmental projects in cancer across 195 different targets. In addition, there are 8 suspended drugs and another 208 drugs where development has been ceased. Learn More

  7. Cancer Immunotherapy: Analytical Tool

    $8,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of immuno-oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  8. Antibodies in Oncology: Analytical Tool

    $4,750.00
    Published by BioSeeker Group on Aug 22nd, 2016
    This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of antibodies in oncology. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More

  9. Antibodies in Oncology Drug Pipeline Update

    $2,250.00
    Published by BioSeeker Group on Aug 4th, 2016
    BioSeeker Group have identified 542 companies plus partners who are today developing 1308 antibody drugs in 3051 developmental projects in cancer across 414 different targets. In addition, there are 4 suspended drugs and another 407 drugs where development has been ceased. Learn More

9 Item(s)

per page

Set Ascending Direction